CSTL Q4 2025 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q4 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$87M+0.8% YoY

Gross Profit

$32M36.6% margin

Operating Income

-$4M-4.4% margin

Net Income

-$2M-2.7% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+4.8%

Cash Flow

Operating Cash Flow

$27M

Free Cash Flow

$20M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$579M

Total Liabilities

$108M

Stockholders' Equity

$471M

Cash & Equivalents

$117M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$87M	$86M	+0.8%
Gross Profit	$32M	$70M	-54.6%
Operating Income	-$4M	$4M	-194.5%
Net Income	-$2M	$10M	-124.3%

Revenue Segments

Dermatologic

$49M100%